Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03361748 · OUTCOME

Time to Progression (TTP)

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma · Source last updated 2025-05-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
From first dose to 24 months after first dose

What was measured

Time from first bb2121 infusion to first documentation of progressive disease (PD), or death due to any cause, whichever occurs first.

Analysis population: All Treated Population

Groups in this outcome

BB2121

BB2121

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
BB2121137

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
BB212110.38Not reported6.1112.06Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        6.11
        upper Limit
        12.06
        value
        10.38
denoms
  1. counts
    1. group Id
      OG000
      value
      137
    units
    Participants
description
Time from first bb2121 infusion to first documentation of progressive disease (PD), or death due to any cause, whichever occurs first.
dispersion Type
95% Confidence Interval
groups
  1. description
    BB2121
    id
    OG000
    title
    BB2121
param Type
MEDIAN
population Description
All Treated Population
reporting Status
POSTED
time Frame
From first dose to 24 months after first dose
title
Time to Progression (TTP)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice